Table 1

HER inhibitors and cell proliferation in parental vs. T100 ovarian cell lines.

A1847

IGROV-1

OVCAR-7

SKOV-3

Parental

T100

Parental

T100

Parental

T100

Parental

T100

Gefitinib

0 μM

1.000 ± 0.055

1.000 ± 0.008

1.000 ± 0.017

1.000 ± 0.057

1.000 ± 0.010

1.000 ± 0.034

1.000 ± 0.008

1.000 ± 0.002

1 μM

0.812 ± 0.006

0.829 ± 0.040

0.998 ± 0.039

0.691 ± 0.026

0.977 ± 0.125

0.899 ± 0.060

0.797 ± 0.060

0.884 ± 0.022

p = 0.001

p = 0.0005

p = 0.93

p = 0.0006

p = 0.96

p = 0.02

p = 0.001

p = 0.0002

Erlotinib

0 μM

1.000 ± 0.075

1.000 ± 0.011

1.000 ± 0.041

1.000 ± 0.037

1.000 ± 0.072

1.000 ± 0.013

1.000 ± 0.027

1.000 ± 0.043

1 μM

0.741 ± 0.063

0.676 ± 0.053

0.753 ± 0.060

0.588 ± 0.046

0.612 ± 0.027

0.653 ± 0.096

0.625 ± 0.031

0.696 ± 0.023

p = 0.0004

p < 10^-4

p = 0.001

p < 10^-6

p = 0.0007

p = 0.001

p = 10^-6

p < 10^-27

Lapatinib

0 μM

1.000 ± 0.007

1.000 ± 0.027

1.000 ± 0.048

1.000 ± 0.062

1.000 ± 0.070

1.000 ± 0.023

1.000 ± 0.108

1.000 ± 0.047

1 μM

0.762 ± 0.063

0.645 ± 0.069

0.789 ± 0.098

0.666 ± 0.031

0.819 ± 0.084

0.673 ± 0.048

0.845 ± 0.023

0.889 ± 0.082

p = 0.001

p = 0.0001

p = 0.005

p < 10^-4

p = 0.006

p < 10^-5

p = 0.03

p = 0.04

Cetuximab

0 μg/ml

1.000 ± 0.091

1.000 ± 0.038

1.000 ± 0.075

1.000 ± 0.067

1.000 ± 0.090

1.000 ± 0.032

1.000 ± 0.031

1.000 ± 0.049

200 μg/ml

0.974 ± 0.027

0.594 ± 0.110

0.892 ± 0.071

0.554 ± 0.067

0.588 ± 0.050

0.657 ± 0.057

0.736 ± 0.038

0.854 ± 0.010

p = 0.57

p = 0.0006

p = 0.07

p < 10^-5

p < 10^-4

p < 10^-4

p < 10^-5

p = 0.002

H3.105

0 μg/ml

1.000 ± 0.071

1.000 ± 0.022

1.000 ± 0.050

1.000 ± 0.050

1.000 ± 0.011

1.000 ± 0.028

1.000 ± 0.040

1.000 ± 0.018

10 μg/ml

0.913 ± 0.095

0.989 ± 0.059

1.006 ± 0.132

0.979 ± 0.152

0.895 ± 0.030

0.856 ± 0.027

0.969 ± 0.039

1.048 ± 0.043

p = 0.14

p = 0.71

p = 0.92

p = 0.78

p = 0.0006

p < 10^-4

p = 0.28

p = 0.07

Parental vs. long-term trastuzumab treated (T100) A1847, IGROV-1, OVCAR-7, and SKOV-3 cells were treated with gefitinib, erlotinib, lapatinib, cetuximab, or H3.105 for 120 hours, and cell proliferation was measured by a WST-1-based colormetric assay. The inter-quartile rule was used to eliminate data outliers before calculating the mean absorbance for untreated and treated cell populations. Fold change in cell numbers is normalized against values determined for untreated cells. Student's T-test was used to calculate p values. Instances where T100 but not parental cell lines were significantly growth inhibited are highlighted in bold.

Wilken et al. Journal of Ovarian Research 2010 3:7   doi:10.1186/1757-2215-3-7